Search Results
Jun 04, 2026, 06:59 ET Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™
Companies in the Biofertilizer MarketThe report profiles key players such as Novonesis (Denmark), UPL Limited (India), Syngenta AG (Switzerland), T. Stanes & Company (India), Lallemand Plant Care (Canada), Rizobacter (Argentina), Gujarat State Fertilizers and Chemicals Ltd (India), Madras Fertilizers
More news about: MarketsandMarkets
Jun 04, 2026, 06:00 ET CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA
simple, wearable devices provide freedom from multiple daily insulin injections.Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation
More news about: CeQur Corporation
Jun 04, 2026, 05:08 ET 歐洲腎臟協會大會：FLOW 試驗指出，司美格魯肽可改善糖尿病及腎病患者的生活質素
里程碑試驗結果顯示，每週用藥一次的司美格魯肽 (Semaglutide) 能顯著提升二型糖尿病 (T2D) 及慢性腎病 (CKD) 成人患者的健康相關生活質素，效果相當於每年多出約八天完全健康的時光。 試驗早前已證明，在中位數 3.4 年的治療期內，與安慰劑比較，司美格魯肽可使主要腎病事件的風險下降 24%，全因死亡率亦下降 20%。 這項新分析帶來以患者為核心的補充證據，顯示司美格魯肽的裨益不僅體現在傳統臨床指標上，更延伸至患者日常生活中的感受及機能表現。對於同時患有二型糖尿病 (T2D) 及慢性腎病 (CKD) 的患者，症狀、治療負擔以及身體機能減弱，都大大影響其日常安康，因此生活質素逐漸成為更重要的治療目標。FLOW
More news about: ERA Congress
Jun 04, 2026, 04:58 ET La bomba de calor aire-agua PHNIX R290 GreenTherm Pro ahora cuenta con la certificación TÜV SÜD RED
https://mma.prnewswire.com/media/2994117/PHNIX_R290_Air_to_Water_Heat_Pump_GreenTherm_Pro_Now_T_V_S_D_RED_Certified__with_a_SCOP_of_5_55_Veri.jpg
More news about: PHNIX
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
marketing application stage, rocbrutinib's dual covalent and non-covalent mechanism enables it to target C481-site and other resistance mutations such as T474I and L528W, providing a scientific basis for overcoming acquired resistance.The recommendation provides authoritative and standardized clinical
More news about: Lupeng Pharmaceutical Ltd
Jun 04, 2026, 02:30 ET AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren's Disease at EULAR 2026
2026.AbolerIS is currently advancing potentially first-in-class immunomodulatory antibodies targeting CD45RC, a key regulator of antigen receptor signaling in T and B cells. Data presented at EULAR 2026 show that CD45RC is highly expressed within lymphocytic infiltrates and selectively localizes to disease-affected
More news about: AbolerIS Pharma
Jun 04, 2026, 00:30 ET Gujarat becomes the New Hub in Organ Transplantation
program can also manage the full spectrum of conditions requiring transplant, such as inborn errors of immunity, bone marrow failure syndromes and CAR T-cell therapy. The packages offered are very nominal (starting from 4 lacs) compared to other bigger cities.The hospital has also been doing great
More news about: Zydus Hospitals and Healthcare Research Private Limited
Jun 03, 2026, 18:23 ET /C O R R E C T I O N -- Oberland Biotech GmbH/
More news about: Oberland Biotech GmbH
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year. The trial previously demonstrated
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year. The trial previously demonstrated
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA-Kongress: Die FLOW-Studie zeigt, dass Semaglutid die Lebensqualität bei Diabetes und Nierenerkrankungen verbessert
vorgestellt wurden, zeigen, dass einmal wöchentlich verabreichtes Semaglutid die gesundheitsbezogene Lebensqualität von Erwachsenen mit Typ-2-Diabetes (T2D) und chronischer Nierenerkrankung (CKD) deutlich verbessert, was etwa acht zusätzlichen Tagen bei voller Gesundheit pro Jahr entspricht. Die
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA学術大会（ERA Congress）：FLOW試験、糖尿病と腎疾患を併存する患者におけるセマグルチドと生活の質改善との関連を示す
この試験ではこれまでに、中央値3.4年の治療期間にわたり、セマグルチドがプラセボと比較して主要な腎疾患イベントのリスクを24％、全死因死亡のリスクを20％低減することが示されています。この新たな分析は、患者中心の補完的なエビデンスを提示するものであり、セマグルチドの有益性が従来の臨床転帰にとどまらず、患者の日常生活における心身の状態や活動能力にも及ぶ可能性を示しています。T2DとCKDを併存する患者では、症状、治療負担、身体機能の低下が日々の心身の健康に大きな影響を及ぼす可能性があるため、QOLはますます重要な治療目標となっています。FLOW試験で無作為に割り付けられた3,533人の参加者のうち、1,767人がセマグルチドの投与を受け、1,766人がプラ
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: El ensayo FLOW muestra beneficios de la semaglutida
demuestran que la administración semanal de semaglutida mejoró significativamente la calidad de vida relacionada con la salud en adultos con diabetes tipo 2 (T2D) y enfermedad renal crónica (ERC), lo que equivale a aproximadamente ocho días adicionales de plena salud al año. El ensayo ya había demostrado
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA 총회: FLOW 임상시험, 세마글루타이드가 당뇨병 및 신장 질환 환자의 삶의 질 개선과 관련 있음을 보여줘
24%, 모든 원인에 의한 사망률을 20% 감소시킨다는 사실을 입증한 바 있다. 이번 새로운 분석은 환자 중심의 보완적 근거를 제시하며, 세마글루타이드의 이점이 전통적인 임상 결과를 넘어 환자가 일상생활에서 느끼고 기능하는 방식까지 확장될 수 있음을 보여준다.T2D와 CKD를 모두 앓는 사람들에게는 증상, 치료 부담, 신체 기능 저하가 일상적인 웰빙에 상당한 영향을 미칠 수 있어 삶의 질이 점점 더 중요한 치료 목표가 되고 있다.FLOW 임상시험에 무작위 배정된 참가자 3533명 중 1767명은 세마글루타이드를,
More news about: ERA Congress
Jun 03, 2026, 17:00 ET Blood Cancer Treatment Allows Hard-to-Match Kidney Failure Patients to Receive a Compatible Kidney Transplant
the most sensitized patients.Repurposing CAR T Therapy for Transplant AccessThe experimental approach combines two engineered T cell therapies: CD19‑targeted CAR T cells, which eliminate memory B cells, and BCMA‑targeted CAR T cells, which deplete antibody‑producing plasma cells.
More news about: NYU Langone Health
Jun 03, 2026, 16:15 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical
More news about: Nektar Therapeutics
Jun 03, 2026, 16:05 ET Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
evaluate safety and tolerability and to determine the recommended dose for further clinical evaluation of ELVN-001 in patients with CML with and without T315I mutations that is relapsed, refractory or intolerant to tyrosine kinase inhibitors (TKIs). Secondary endpoints include pharmacokinetics, major molecular
More news about: Enliven Therapeutics, Inc.
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
therapies in the control arm."LOTIS-5 was designed to address a clear unmet need in r/r DLBCL in patients who cannot access or who progress on a CAR-T or other complex therapies," said Mehdi Hamadani, MD, Professor of Medicine, Associate Director of Clinical Research, Section Chief of Hematologic Malignancies
More news about: ADC Therapeutics SA
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
zielgerichtete Immuntherapie ihrer Klasse, die von Amgen-Forschern entwickelt wurde, um sowohl an DLL3 auf Tumorzellen als auch an CD3 auf T-Zellen zu binden und dadurch T-Zellen zu aktivieren, um DLL3-exprimierende SCLC-Zellen abzutöten. Dies führt zur Bildung einer zytolytischen Synapse mit Lyse der Krebszelle.
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
de sa catégorie, conçue par les chercheurs d'Amgen pour se lier à la fois au DLL3 sur les cellules tumorales et au CD3 sur les cellules T, activant ainsi les cellules T pour qu'elles tuent les cellules CPPC exprimant DLL3. Il en résulte la formation d'une synapse cytolytique avec lyse de la cellule cancéreuse.
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
viceprezident divízie onkológie spoločnosti Amgen. „Schválenie lieku IMDYLLTRA Európskou komisiou – ako prvej a jedinej terapie využívajúcej T-bunkové aktivátory (T-cell engager) schválenej na liečbu malobunkového karcinómu pľúc – predstavuje dôležitý krok vpred pre pacientov v Európe a odráža náš záväzok
More news about: Amgen
Jun 03, 2026, 14:19 ET Pet Partners Invites Supporters to Join the 2026 World's Largest Pet Walk
Partners. Fundraisers who reach designated milestones by August 14 will qualify for event incentives including special commemorative bandannas, a t-shirt, and additional items at higher incentive levels. Participants can also compete for recognition through the Sneaker Awards, which celebrate standout
More news about: Pet Partners
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin
More news about: Amgen